Saturday 17 October 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRD Healthcare Biotechnology
In the quarter to June 2026, revenue grew 20.3%, EPS fell 235.3% and free cash flow fell 57.3%, each against the same quarter a year earlier.
1.01
0.06
−5.61%
Follow TVRD
Tvardi Therapeutics, Inc. (TVRD) P/E ratio
Tvardi Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 240× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 168× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 2.7× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 240×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| TVRD Tvardi Therapeutics, Inc. | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| CLVSQ Clovis Oncology, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)